Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06295367 · ClinicalTrials.gov registry record · NA

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

A NA study of Malignant Solid Neoplasm, sponsored by ECOG-ACRIN Cancer Research Group.

Recruiting
Registry status
NA
Development phase
760
Enrollment target
20
Study locations

NCT06295367: Recruiting NA study of Malignant Solid Neoplasm, sponsored by ECOG-ACRIN Cancer Research Group.

NCT06295367 is a NA study of Malignant Solid Neoplasm that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 760 participants, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06295367, a NA study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.

RECRUITING
Registry status
NA
Development phase
760 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.

Primary Outcome

Cost-related cancer care non-adherence is defined as a positive response to any of the following due to costs: Delayed, forewent, stopped, or changed prescribed cancer medication; or delayed, forewent, or refused recommended cancer tests, or cancer office visits. Will be calculated as a report of non-adherence at any point up through the 12mo follow-up survey.

Conditions Studied

Malignant Solid Neoplasm

Interventions

  • OTHER Survey Administration
  • OTHER Best Practice
  • OTHER Interview
  • OTHER Financial Navigation

Study Locations (20)

Colorado

  • Rocky Mountain Cancer Centers-Aurora - Aurora
  • Boulder Community Foothills Hospital - Boulder
  • Rocky Mountain Cancer Centers-Boulder - Boulder
  • Rocky Mountain Cancer Centers - Centennial - Centennial
  • The Women's Imaging Center - Denver
  • Colorado Blood Cancer Institute - Denver
  • Presbyterian - Saint Lukes Medical Center - Health One - Denver
  • Rocky Mountain Cancer Centers-Midtown - Denver
  • Rocky Mountain Cancer Centers-Rose - Denver
  • Mountain Blue Cancer Care Center - Swedish - Englewood
  • Rocky Mountain Cancer Centers - Swedish - Englewood
  • The Melanoma and Skin Cancer Institute - Englewood
  • Rocky Mountain Cancer Centers-Lakewood - Lakewood
  • Rocky Mountain Cancer Centers-Littleton - Littleton
  • Rocky Mountain Cancer Centers-Sky Ridge - Lone Tree

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CARTI Cancer Center - Little Rock

California

  • Contra Costa Regional Medical Center - Martinez
  • BASS Medical Group - Lennon - Walnut Creek

Alaska

  • Fairbanks Memorial Hospital - Fairbanks

Trial Details

FieldValue
Enrollment Target 760 participants
Start Date 2024-02-29
Est. Completion 2027-12-01
Phase NA
ECOG-ACRIN Cancer Research Group

75 total trials

What NCT06295367 shows while recruiting

NCT06295367 is an interventional study that assigns participants to a tested intervention. The registered 760 participants enrollment target is mid-sized for trials with a published cap, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (33% lower).

The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.

NCT06295367 names 20 study sites across 4 states, led by Colorado, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT06295367 about?

NCT06295367 is a clinical study titled "Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)". This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, incom...

What is the current status of trial NCT06295367?

This trial is currently recruiting. It is a NA study. The enrollment target is 760 participants. The study started on 2024-02-29. Estimated completion is 2027-12-01.

What conditions does trial NCT06295367 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm.

What interventions are being tested in trial NCT06295367?

The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Interview (OTHER), Financial Navigation (OTHER).

Who is sponsoring clinical trial NCT06295367?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06295367 being conducted?

This trial has 20 study locations across Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06295367's enrollment target sits among peer trials

760 22nd of 176 higher than 155 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02089607 · 760 participants · NA

    CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft

  • NCT04073706 · 760 participants · Phase 3

    Sentinel Node Biopsy in Endometrial Cancer

  • NCT05129228 · 760 participants · NA

    Optical Coherence Tomography of the Saphenous Vein Graft

  • NCT05787821 · 760 participants

    Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06295367

Source: ClinicalTrials.gov NCT06295367, the US trial registry maintained by the National Library of Medicine. NCT06295367 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.